Sort   by:  
 Page size 
UnknownQuality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.
Not available
S-EPMC5891128 | biostudies-literature
UnknownPhase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.
Not available
S-EPMC3454772 | biostudies-literature
UnknownAccelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.
Not available
S-EPMC4050203 | biostudies-literature
UnknownPhase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.
Not available
S-EPMC6804828 | biostudies-literature
UnknownNivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
Not available
S-EPMC4806782 | biostudies-literature
UnknownSafety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.
Not available
S-EPMC7587408 | biostudies-literature
UnknownChemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
Not available
S-EPMC5891129 | biostudies-literature
UnknownSeven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.
Not available
S-EPMC5805480 | biostudies-literature
Sort   by:  
 Page size